ArticleFrontiers in oncology2026
Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Prognostic Performance of Nutritional Indices in Acute Myeloid Leukemia.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) prognosis is influenced by numerous parameters. The prognostic nutritional index (PNI), neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) have emerged as potential prognostic markers in various malignancies. Objectives: To evaluate the prognostic significance of PNI, NLR, and PLR in predicting overall survival (OS) in newly diagnosed MM patients. Methods: This retrospective study included 97 patients diagnosed with MM at the Hematology Clinic of Afyonkarahisar Health Sciences University between May 2017 and June 2025. PNI, NLR, and PLR values were calculated from baseline laboratory data at diagnosis. Overall survival was analyzed using Kaplan-Meier curves and Cox proportional hazards regression models. Results: The median follow-up time was 22.3 months (interquartile range: 6.8-48.0 months). Low PNI (≤34.7) was identified in 38 patients (39.2%). The low PNI group demonstrated significantly higher mortality compared to the high PNI group (76.3% vs. 50%, p = 0.02). Median OS was significantly shorter in the low PNI group compared to the high PNI group (13.5 months vs. 53.3 months, p = 0.007). No significant differences in median OS were observed between low and high PLR or NLR groups. High beta-2 microglobulin (β2M) levels were associated with a 3.19-fold increased risk of death (p = 0.048). Conclusion: Low PNI at diagnosis is significantly associated with increased mortality and reduced overall survival in MM patients, whereas NLR and PLR do not demonstrate significant prognostic value in this cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.